Because NPM1-mutated leukemic cells also tend to express the CD33 cell surface antigen, gemtuzumab ozogamicin can be added to standard intensive regimens to improve survival in favorable- and intermediate-risk AML [33]. This evidence concerns the gene NPM1 and acute myeloid leukemia.